Details of the Drug
General Information of Drug (ID: DMG6LJ8)
| Drug Name |
AW-00430
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
MLS000849730; SMR000455748; N-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide; N2-(4-bromo-2-chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)thiophene-2-sulfonamide; Bio1C2; AW-00430; AC1Q2OSF; AC1MDU2J; Oprea1_610998; CHEMBL212314; cid_2795741; BDBM58217; MolPort-001-805-761; HMS2792P22; ZINC1023475; MCULE-6709059808; N-(4-bromo-2-chlorophenyl)-5-(2-methyl-4-thiazolyl)-2-thiophenesulfonamide; N-(4-bromo-2-chloro-phenyl)-5-(2-methylthiazol-4-yl)thiophene-2-sulfonamide
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 449.8 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.9 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


